From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma by Christopher Montemagno, Shamir Cassim, Jacques Pouyssegur, Alexis Broisat, Gilles Pagès

“…The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last 10 years, a growing interest pointing towards mesothelin (MSLN) as a promising PDAC-associated antigen has emerged. …”
Get full text

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? by Christopher Montemagno, Shamir Cassim, Nicolas De Leiris, Jérôme Durivault, Marc Faraggi, Gilles Pagès

“…The lack of accurate diagnostic tests and failure of conventional therapies contribute to this pejorative issue. Over the last decade, the advent of theranostics in nuclear medicine has opened great opportunities for the diagnosis and treatment of several solid tumors. …”
Get full text